Marshall Wace, LLP Genfit S.A. Transaction History
Marshall Wace, LLP
- $63.3 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding GNFT
# of Institutions
7Shares Held
76.8KCall Options Held
0Put Options Held
0-
Israel Englander Millennium Management LLC | New York, Ny29.7KShares$123,6220.0% of portfolio
-
Morgan Stanley New York, NY28.5KShares$118,4100.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il16.8KShares$70,0250.0% of portfolio
-
Optiver Holding B.V. Amsterdam, P7963Shares$4,0060.0% of portfolio
-
Rhumbline Advisers Boston, MA678Shares$2,8200.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $207M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...